

# How to: Conduct a Health Technology Assessment (HTA) Landscaping Review

Linda Murphy

In the third of our new how-to series, Lumanity's Linda Murphy explores the importance of conducting a Health Technology Assessment (HTA) Landscaping Review, offering key insights and considerations for an effective evaluation.




## What is a Health Technology Assessment (HTA) landscaping review?

- Bringing a new technology to market requires an understanding of the HTA landscape into which a company plans to launch. This includes how previous therapies were assessed
- An HTA landscaping review is a targeted review of previous HTA appraisals in countries of interest for a specific indication or proxy indication. It involves the extraction of both quantitative and qualitative information from previous HTA appraisals, with the objective of identifying key learnings related to a certain HTA situation and development of strategic recommendations on the basis of those learnings

## When should you do an HTA landscaping review?

- An HTA landscaping review should be conducted as early as possible (ideally when the technology enters Phase 1) so that the company requesting the review can plan for any foreseen gaps. The review can be conducted at multiple stages, i.e. updated if new appraisals of interest emerge



## Why is an HTA landscaping review useful?



HTA bodies will only accept a technology's value proposition if there is robust evidence and minimal uncertainty to support it. An HTA landscaping review allows companies to compare their planned or existing evidence base against HTA requirements. It supports identification of key areas of uncertainty, HTA agency feedback on these and the requirements to resolve the uncertainty. This is valuable to companies because it allows them to optimize their evidence generation strategies and submissions by identifying argumentation and approaches that have previously been successful and identifying challenges that other companies have faced in a similar environment



Learnings from an HTA landscaping review, bolstered by our strategic recommendations on the basis of those learnings, allows companies to plan and improve the likelihood of HTA success



An HTA landscape review will typically support several activities such as a health economics and outcomes research (HEOR) evidence generation strategy, the generation of an early cost-effectiveness model and submission plan

# How to tailor an HTA landscaping review to a company's need

- The company will provide information regarding their clinical trial data and modelling strategy, if available. This will allow the reviewer to identify potential challenges that the product may face at HTA and explore how these challenges were addressed in previous appraisals. It will also help us to target our review and data extraction around information that is of interest for the product in question
- An HTA landscape review can be broad or can focus on specific research questions. For example, what surrogate endpoints were used in oncology submissions to the National Institute for Health and Care Excellence (NICE) and how were they validated and accepted; summary of economic analysis in a specific indication – model structure, health states, model assumptions, data used and key decision drivers. Ultimately the HTA landscaping review is conducted to address company specific research questions
- HTA needs differ by country, therefore, an HTA landscaping review aims to capture and understand the nuanced differences between the countries of interest. The HTA landscaping review can be conducted for a range of countries or collaborations (e.g. NICE, Haute Autorité de Santé (HAS) or Joint Clinical Assessment (JCA), BeNeLuxA Initiative) as requested by a company. The review will typically summarize the data for the countries of interest allowing a cross-country comparison
- An HTA landscaping review can also include a summary of HTA roadmaps summarizing the HTA guideline requirements for the countries of interest
- In summary, an HTA landscaping review is tailored to suit the needs of the company that requests it ensuring it is fit for purpose

## Key steps involved in an HTA landscaping review:

**Identify** the indication or proxy indications.

**Identify** the countries of interest or collaborations of interest.

**Provide** clinical trial data and modelling strategy, if available.

**Identify** the research questions or key topics to cover.

**Conduct** targeted desktop searches to retrieve the HTA documents of interest.

**Summarize** key decision drivers, key areas of uncertainty and HTA acceptance/non-acceptance across the countries of interest.

**Identify** argumentation and approaches that have previously been successful and challenges that other companies have faced in a similar environment.

**Summarize** what this means for the company – how does the company's evidence base compare against the HTA requirements and what are the key considerations for planning and evidence generation.

**Summarize** learnings from the HTA landscaping review, summarize the strategic recommendations on the basis of those learnings.

## About the author

Have a question for our author? Use the links below to contact them directly on LinkedIn or by email.



**Linda Murphy**  
Senior Director, Value  
Demonstration and Early  
Value and HEOR Strategy Lead



We hope you enjoyed the third in our series explaining how to undertake early HEOR evidence generation activities.

Follow our [VAO LinkedIn channel](#) to find out when the next in the series is published.